|
1) Vaziri ND, Zhou XJ, Liao SY. Erythropoietin enhances recovery from cisplatin-induced acute renal failure. Am J Physiol. 1994; 266: F360-6
|
|
|
|
2) Nemoto T, Yokota N, Keane WF, et al. Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure. Kidney Int. 2001; 59: 246-51
|
|
|
|
|
|
3) Johnson DW, Pat B, Vesey DA, et al. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int. 2006; 69: 1806-13
|
|
|
|
|
4) Spandou E, Tsouchnikas I, Karkavelas G, et al. Erythropoietin attenuates renal injury in experimental acute renal failure ischaemic/reperfusion model. Nephrol Dial Transplant. 2006; 21: 330-6
|
|
|
|
|
|
5) Goldfarb M, Rosenberger C, Ahuva S, et al. A role for erythropoietin in the attenuation of radiocontrast-induced acute renal failure in rats. Ren Fail. 2006; 28: 345-50
|
|
|
|
|
|
6) Kolyada AY, Liangos O, Madias NE, et al. Protective effect of erythropoietin against radiocontrast-induced renal tubular epithelial cell injury. Am J Nephrol. 2008; 28: 203-9
|
|
|
|
|
|
7) Imamura R, Isaka Y, Ichimaru N, et al. Carbamylated erythropoietin protects the kidneys from ischemia-reperfusion injury without stimulating erythropoiesis. Biochem Biophys Res Commun. 2007; 353: 786-92
|
|
|
|
|
|
8) Okada T, Sawada T, Kubota K. Asialoerythropoietin has strong renoprotective effects against ischemia-reperfusion injury in a murine model. Transplantation. 2007; 84: 504-10
|
|
|
|
|
|
9) Yokomaku Y, Sugimoto T, Kume S, et al. Asialoerythropoietin prevents contrast-induced nephropathy. J Am Soc Nephrol. 2008; 19: 321-8
|
|
|
|
|
|
10) Bahlmann FH, Song R, Boehm SM, et al. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation. 2004; 110: 1006-12
|
|
|
|
|
|
11) Park SH, Choi MJ, Song IK, et al. Erythropoietin decreases renal fibrosis in mice with ureteral obstruction: role of inhibiting TGF-beta-induced epithelial-to-mesenchymal transition. J Am Soc Nephrol. 2007; 18: 1497-507
|
|
|
|
|
|
12) Menne J, Park JK, Shushakova N, et al. The continuous erythropoietin receptor activator affects different pathways of diabetic renal injury. J Am Soc Nephrol. 2007; 18: 2046-53
|
|
|
|
|
|
13) Eto N, Wada T, Inagi R, et al. Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression. Kidney Int. 2007; 72: 455-63
|
|
|
|
|
|
14) Logar CM, Brinkkoetter PT, Krofft RD, et al. Darbepoetin alfa protects podocytes from apoptosis in vitro and in vivo. Kidney Int. 2007; 72: 489-98
|
|
|
|
|
|
15) Katavetin P, Inagi R, Miyata T, et al. Erythropoietin induces heme oxygenase-1 expression and attenuates oxidative stress. Biochem Biophys Res Commun. 2007; 359: 928-34
|
|
|
|
|
|
16) Katavetin P, Tungsanga K, Eiam-Ong S, et al. Antioxidative effects of erythropoietin. Kidney Int Suppl. 2007; 107: S10-5
|
|
|
|
|
|
17) Kuriyama S, Tomonari H, Yoshida H, et al. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron. 1997; 77: 176-85
|
|
|
|
|
|
18) Gouva C, Nikolopoulos P, Ioannidis JP, et al. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int. 2004; 66: 753-60
|
|
|
|
|
|
19) Drueke TB, Locatelli F, Clyne N, et al. CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006; 355: 2071-84
|
|
|
|
|
|
20) Singh AK, Szczech L, Tang KL, et al. CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355: 2085-98
|
|
|
|
|
|
21) Levin A. Understanding recent haemoglobin trials in CKD: methods and lesson learned from CREATE and CHOIR. Nephrol Dial Transplant. 2007; 22: 309-12
|
|
|
|
|
|
22) Rieves D, Pan DG. Public Health Service, Food and Drug Administration Silver Spring, MD20993, 2007 (http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4315b1-01-FDA.pdf)
|
|
|
|
|
|
23) Cody J, Daly C, Campbell M, et al. Recombinant human erythropoietin for chronic renal failure patients(Review). Cochrane review in the Cochrane Library Issue 1. 2008. p. 1-51
|
|
|
|
|
|
24) Mix TC, Brenner RM, Cooper ME, et al. Rationale - Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J. 2005; 149: 408-13
|
|
|
|
|